CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
845 results found-
CSL Vifor expects to launch sparsentan in the UK in the second half of 2025
https://newsroom.csl.com/2025-05-23-Englands-NICE-recommends-FILSPARI-R-sparsentan-as-a-treatment-option-for-IgA-nephropathy -
CSL engages stakeholders and periodically undertakes a formal materiality assessment process to understand our relevant sustainability-related topics.
https://www.csl.com/sustainability/governance/stakeholder-engagement-and-material-topics -
CSL’s Code of Conduct (the Code) sets the standards for how we conduct business in an ethical and transparent way through our commitment to governance and compliance with all applicable laws, regulations and industry standards.
https://www.csl.com/sustainability/governance/ethics-and-transparency -
CSL Vifor expects to launch FILSPARI in the first European markets in the second half of 2024.
https://newsroom.csl.com/2024-04-24-CSL-Vifor-and-Travere-Therapeutics-Announce-European-Commission-approves-FILSPARI-R-sparsentan-for-the-treatment-of-IgA-Nephropathy -
Iron deficiency affects about half of the patients suffering from chronic kidney disease.
https://newsroom.csl.com/2023-11-24-Iron-Deficiency-Day-2023-CSL-Vifor-calls-for-access-to-iron-deficiency-diagnosis-and-treatment -
In Canada, Ferinject ® is commercialized through CSL Behring Canada, Inc., with availability expected in the second half of 2024.
https://newsroom.csl.com/2024-03-19-Ferinject-R-approved-by-Health-Canada-for-the-treatment-of-iron-deficiency-anemia-in-adult-and-pediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure -
11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL's second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
October 2024 February 2025 CSL held its 2024 AGM on CSL held a virtual investor briefing + READ MORE AT 29 October 2024 where it following the release of its half-year INVESTORS.CSL.COM announced the appointment results, with the briefing materials of Dr Brian Daniels to the Board, released to the ASX on 11 February 2025.
https://www.csl.com/-/media/csl/documents/csl-governance-docs/corporate-governance-statement-2025.pdf -
Franking Amount per share Total dividend Dividend Date paid per share US$ US$ Final dividend 2 October 2024 Unfranked 145 cents $703m for the year ended 30 June 2024 Interim dividend 5 April 2025 Unfranked 130 cents $631m for the half year ended 31 December 2024
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf -
During FY2025, over half of the studies started by CSL included remote include representative options for participants.
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-sustainability-fact-sheet-2025.pdf